Lai et al., 2025 - Google Patents
Knockdown of GSDMD inhibits pyroptosis in psoriasis by blocking the NOD-like receptor signaling pathwayLai et al., 2025
- Document ID
- 11548943996616236244
- Author
- Lai S
- Chen H
- Ji X
- Zhu W
- Wu Z
- Huang S
- Lin C
- Yang T
- Zeng Z
- Li L
- Publication year
- Publication venue
- International Immunopharmacology
External Links
Snippet
Background Psoriasis is a chronic inflammatory skin disease regulated by autoimmunity, and pyroptosis plays an important role in this condition. This research sought to examine the function and potential molecular pathway of Gasdermin D (GSDMD) in psoriasis. Methods …
- 102100037388 Gasdermin-D 0 title abstract description 148
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abby et al. | Notch1 mutations drive clonal expansion in normal esophageal epithelium but impair tumor growth | |
| Maschalidi et al. | Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes | |
| Lv et al. | Single cell RNA-seq analysis identifies ferroptotic chondrocyte cluster and reveals TRPV1 as an anti-ferroptotic target in osteoarthritis | |
| Liu et al. | Perfluoroalkyl substances promote breast cancer progression via ERα and GPER mediated PI3K/Akt and MAPK/Erk signaling pathways | |
| Seegren et al. | Reduced mitochondrial calcium uptake in macrophages is a major driver of inflammaging | |
| Steiling et al. | A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment | |
| Dai et al. | B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma | |
| Lin et al. | Melatonin suppresses neuropathic pain via MT2-dependent and-independent pathways in dorsal root ganglia neurons of mice | |
| Tsai et al. | Neutrophil extracellular trap production and CCL4L2 expression influence corticosteroid response in asthma | |
| Zagozewski et al. | An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate | |
| Chen et al. | Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice | |
| Koch et al. | Quantitative proteomics identifies reduced NRF2 activity and mitochondrial dysfunction in atopic dermatitis | |
| Huang et al. | HSP60 Regulates Monosodium Urate Crystal‐Induced Inflammation by Activating the TLR4‐NF‐κB‐MyD88 Signaling Pathway and Disrupting Mitochondrial Function | |
| Lai et al. | Knockdown of GSDMD inhibits pyroptosis in psoriasis by blocking the NOD-like receptor signaling pathway | |
| Xie et al. | Integrin α4 up-regulation activates the hedgehog pathway to promote arsenic and benzo [α] pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis | |
| Kim et al. | Single-cell RNA sequencing of human nail unit defines RSPO4 onychofibroblasts and SPINK6 nail epithelium | |
| Wang et al. | Upregulated miR-29c suppresses silica-induced lung fibrosis through the Wnt/β-catenin pathway in mice | |
| Huang et al. | Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway | |
| Li et al. | Exploration of berberine against ulcerative colitis via TLR4/NF-κB/HIF-1α pathway by bioinformatics and experimental validation | |
| Zheng et al. | S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity | |
| Deng et al. | Liquiritin exerts psoriasis therapy and prevention by regulating the YY1/RBP3 axis | |
| Wang et al. | Restoring Treg/Th17 cell balance in ulcerative colitis through HRas silencing and MAPK pathway inhibition | |
| Wang et al. | CTSL Promotes Autophagy in Laryngeal Cancer Through the IL 6‐JAK‐STAT 3 Signalling Pathway | |
| Yamamoto et al. | Anti-HBV drug entecavir ameliorates DSS-induced colitis through PD-L1 induction | |
| Zhou et al. | CCR1hi/CCL5hi macrophage-mediated CCL5hi T cell chemotaxis in salivary gland aggravates Sjögren’s syndrome |